Pomerantz LLP is investigating claims on behalf of investors of Alibaba Group Holding Limited concerning whether Alibaba and certain officers or directors engaged in securities fraud or unlawful business practices. The investigation follows a June 24, 2026 Financial Times report that Anthropic accused Alibaba of obtaining illicit access to its Claude AI model through fake accounts, after which Alibaba’s American Depositary Receipt price fell $7.53 per ADR, or 7.34%, over two trading sessions to close at $95.07 per ADR on June 25, 2026. Subsequently, on July 1, 2026, the U.S. Department of Justice announced Alibaba entered a non-prosecution agreement to pay $600 million to resolve allegations of violating the Federal Food, Drug, and Cosmetic Act by failing to prevent merchants from selling and importing illegal pharmaceuticals and related items into the United States, causing the ADR price to fall $1.85 per ADR, or 1.9%, to close at $96.14 per ADR on July 2, 2026.
Alibaba Group Holding LtdDOJ non-prosecution agreement and $600M payment for illegal pharmaceuticals, plus securities fraud investigation.
Anthropic accused Alibaba of illicit access to its Claude AI model, but impact on Anthropic is indirect.
